Jakafi ruxolitinib regulatory update

FDA approved an sNDA from Incyte for Jakafi ruxolitinib to treat polycythemia vera (PV) in patients who have had an inadequate response to or are intolerant of hydroxyurea. Incyte said Jakafi is the f...